Reviewing Arena Pharmaceuticals Inc. (ARNA)’s and Recro Pharma Inc. (NASDAQ:REPH)’s results

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) and Recro Pharma Inc. (NASDAQ:REPH), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arena Pharmaceuticals Inc. 24.69M 97.31 111.28M -2.72 0.00
Recro Pharma Inc. 78.61M 2.35 62.51M -2.76 0.00

Table 1 demonstrates Arena Pharmaceuticals Inc. and Recro Pharma Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides us Arena Pharmaceuticals Inc. and Recro Pharma Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Arena Pharmaceuticals Inc. -450.71% -23.8% -19.7%
Recro Pharma Inc. -79.52% -273.4% -34.7%

Volatility & Risk

Arena Pharmaceuticals Inc.’s 1.77 beta indicates that its volatility is 77.00% more volatile than that of Standard & Poor’s 500. From a competition point of view, Recro Pharma Inc. has a -0.58 beta which is 158.00% less volatile compared to Standard & Poor’s 500.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Arena Pharmaceuticals Inc. and Recro Pharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arena Pharmaceuticals Inc. 0 0 2 3.00
Recro Pharma Inc. 0 0 1 3.00

The upside potential is 19.29% for Arena Pharmaceuticals Inc. with average target price of $58.

Insider and Institutional Ownership

Institutional investors held 84.1% of Arena Pharmaceuticals Inc. shares and 67.4% of Recro Pharma Inc. shares. Insiders held 0.1% of Arena Pharmaceuticals Inc. shares. Competitively, insiders own roughly 6.09% of Recro Pharma Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arena Pharmaceuticals Inc. 0% 6.05% 2.96% -15.18% 30.07% 20.72%
Recro Pharma Inc. 19.79% 7.96% 1.42% 47.65% -18.87% -14.92%

For the past year Arena Pharmaceuticals Inc. has 20.72% stronger performance while Recro Pharma Inc. has -14.92% weaker performance.

Summary

Arena Pharmaceuticals Inc. beats Recro Pharma Inc. on 6 of the 10 factors.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The companyÂ’s proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.